PREPARATION AND PURIFICATION
BioPharm: Downstream processing is largely considered the second half of a typical biopharmaceutical manufacturing process. What are the typical steps involved in the downstream process?Nelligan: The steps that biopharma manufacturers rely on for downstream processing are quite well established. A typical biopharmaceutial process uses three chromatographic column steps, each preceded by ultra filtration/diafiltration (UF/DF) of product. Each UF/DF pretreatment step is necessary to prepare the product for the following chromatography stage because all columns operate under differing pH or molarity conditions. Basically, the product needs to be primed for chromatography use beforehand. UF/DF concentrates and resuspends the product in the correct buffer before it is placed into the columns, making for a faster and more efficient process
In a typical three-stage downstream purification process, the strategy is as follows:
BioPharm: What are the major challenges associated with the chromatography?
Nelligan: Yes, there are common challenges. For instance, the gel or resin used to recover and purify product can deteriorate with time; its activity is lost as the gel is recycled multiple times to maximize use. The gel is often made of tiny beads (a few microns in diameter) that tend to compress when packed. If too much pressure is applied, the beads in the gel can collapse, thereby producing small fragments or fines. Liquid flow through the columns is restricted by these fragments. As a result, capacity and activity can be lost. A typical chromatography column can comprise many hundreds of liters of gel but the bed height is rather flat (approximately 20 cm). Therefore, columns are shallow but wide (e.g., 2 m) to avoid over pressurization and compression of the resin beads.
The proteins we make are very delicate. The conditions on the columns can lead to protein degradation if they are not managed properly. Consider, for example, an everyday egg, which happens to be a protein covered in a hard shell for protection. If we shake the egg too much, it deforms. The process is irreversible.
Biopharmaceutical products are just as friable as the egg example. If we agitate a protein too much, expose it to air for too long, or fail to store it at the correct temperature, the protein can degrade and product loss can occur. At the end of a typical downstream process, the protein yield is often down to 60% of the starting concentration (i.e. for every kilogram processed, 40% is lost). Even though the industry spends a lot of time trying to optimize their processes to be efficient, these losses are difficult to recover.